May 23, 2024 07:12 AM EDT
Deals
R&D

As­traZeneca taps more Chi­na-de­rived tech with $19M can­cer deal for Nona an­ti­bod­ies

Ayisha Sharma

News Reporter

As­traZeneca on Thurs­day inked a li­cense and op­tion deal with the US off­shoot of a Chi­nese-Dutch com­pa­ny, with an eye to cre­at­ing an­ti­body-based tar­get­ed can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times